Thrombin inhibition by dabigatran attenuates atherosclerosis in ApoE deficient mice.
about
Oxidative stress in the pathogenesis of atherothrombosis associated with anti-phospholipid syndrome and systemic lupus erythematosus: new therapeutic approachesNew Insights into the Pros and Cons of the Clinical Use of Vitamin K Antagonists (VKAs) Versus Direct Oral Anticoagulants (DOACs)Platelets and their chemokines in atherosclerosis-clinical applications.Inhibition of Thrombin With PPACK-Nanoparticles Restores Disrupted Endothelial Barriers and Attenuates Thrombotic Risk in Experimental AtherosclerosisThrombin Generation and Atherothrombosis: What Does the Evidence Indicate?Parenteral administration of factor Xa/IIa inhibitors limits experimental aortic aneurysm and atherosclerosis.The hemostatic system as a regulator of inflammation in atherosclerosis.Coagulation and non-coagulation effects of thrombin.Genetic disruption of multidrug resistance-associated protein 1 improves endothelial function and attenuates atherosclerosis in MRP1-/- LDLr-/- double knockout mice.Dabigatran etexilate retards the initiation and progression of atherosclerotic lesions and inhibits the expression of oncostatin M in apolipoprotein E-deficient miceDabigatran and apolipoprotein B.Anti-inflammatory and antiplatelet effects of non-vitamin K antagonist oral anticoagulants in acute phase of ischemic stroke patients.Dual Anticoagulant and Antiplatelet Therapy for Coronary Artery Disease and Peripheral Artery Disease Patients.Noncanonical Matrix Metalloprotease 1-Protease-Activated Receptor 1 Signaling Drives Progression of Atherosclerosis.
P2860
Q28075691-E15AFE7A-8E5A-4987-A90D-4933C6FB5E01Q28081366-D4424383-E97E-4945-B73A-F56C47AD01E0Q34019069-D14495A7-4A33-4702-B67C-CBC45C4B2651Q35894640-68EB800A-E812-44D0-8DF9-51483644C40CQ37240386-39BF28A0-4052-4DB6-AF1A-C113D5C779D4Q37654883-790CCE85-3F0D-4989-8461-D3E4CFEA1A75Q38285796-C0FE8C46-A099-496C-A3A6-9D34FEADF3B3Q38924721-5E2333D3-8C6D-4415-8957-5D09502269E4Q41015232-32A73608-D503-4C60-BA97-67E1EB6A1D57Q41812796-11644B56-AF1C-4463-862A-0B3009E3CD81Q43082536-9CFE6BDB-EA41-4A0E-AD71-232A85F02CBFQ47863451-26079071-E584-45CD-9085-6C4D44DCD51FQ49960669-F2D08CB2-0054-44B0-8F9A-30953B449422Q52721277-40ADC9A3-84A2-479C-9296-177C0FD9181A
P2860
Thrombin inhibition by dabigatran attenuates atherosclerosis in ApoE deficient mice.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh
2014年學術文章
@zh-hant
name
Thrombin inhibition by dabigatran attenuates atherosclerosis in ApoE deficient mice.
@en
type
label
Thrombin inhibition by dabigatran attenuates atherosclerosis in ApoE deficient mice.
@en
prefLabel
Thrombin inhibition by dabigatran attenuates atherosclerosis in ApoE deficient mice.
@en
P2093
P2860
P356
P1476
Thrombin inhibition by dabigatran attenuates atherosclerosis in ApoE deficient mice.
@en
P2093
Cornelius Mueller
Georg Nickenig
Jens Mueller
Nikos Werner
Simon Pingel
Vedat Tiyerili
P2860
P304
P356
10.5114/AOMS.2014.40742
P577
2014-02-23T00:00:00Z